Search for: "Lee v. Price et al"
Results 41 - 60
of 74
Sort by Relevance
|
Sort by Date
19 Dec 2012, 4:08 pm
Psychiatry Piquero, Alex R., et al. [read post]
30 Apr 2012, 11:19 am
James III, et al. [read post]
13 Feb 2012, 11:05 am
Risk-based pricing and risk-reducingeffort: does the private insurancemarket reduce environmental accidents? [read post]
28 Nov 2011, 8:57 pm
MF Global's Missing Customer Funds and Its Implications on the Futures Industry By R. [read post]
19 Sep 2011, 9:36 am
V. [read post]
31 Aug 2011, 10:27 am
More focused arbitration – covering price-adjustment clauses – is common even in the largest private target bids. [read post]
14 Jul 2011, 9:23 am
[ET AL.] [read post]
13 Jul 2011, 11:49 am
[ET AL.] [read post]
5 Feb 2011, 10:22 am
If the market is competitive, a party making a take it-or-leave it offer must set price and other terms that will lead to sales despite the absence of particularized negotiations. [read post]
28 Jan 2011, 1:04 pm
[et al.]. [read post]
22 Dec 2010, 11:36 am
HUGH CASSIDY et al., Defendants, Cross-Complainants, and Respondents, WILLIAM STRAW, Cross-Defendant and Appellant. [read post]
22 Dec 2010, 11:36 am
HUGH CASSIDY et al., Defendants, Cross-Complainants, and Respondents, WILLIAM STRAW, Cross-Defendant and Appellant. [read post]
2 Dec 2010, 9:16 am
[et al.] ; edited by Junwei Fu, Jacob S. [read post]
26 Oct 2010, 10:25 pm
See David Michael et al, Beyond the Great Wall, Intellectual Property Strategies for Chinese Companies, Boston Consulting Group, January 2007. [read post]
4 Sep 2010, 4:05 am
John Stossel et al. [read post]
7 Jun 2010, 10:04 am
§9601 et seq. [read post]
7 Jun 2010, 9:54 am
§9601 et seq. [read post]
10 May 2010, 1:16 pm
The following is a summary review of articles from all over the nation concerning environmental law settlements, decisions, regulatory actions and lawsuits filed during the past week. [read post]
17 Apr 2010, 11:03 am
No. 140 (S.C.); Lee v. [read post]
1 Apr 2010, 3:04 am
– TRIPS and price controls on patented pharmaceutical products (patentidbits) Assessing pharma patent strength (JIPLP) Canada: Health Canada releases final guidances on biosimilars (Pharmacapsules) US: District Court S D New York: ‘Isolated DNA’ patents fail to claim patentable subject matter: Association for Molecular Pathology and ACLU v. [read post]
